Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for GRI-0621 in Idiopathic pulmonary fibrosis (IPF). The expected timing is based on the latest available company guidance and may change.
05/14/26:- Ph2a GRI-0621-IPF-02 data showed zero cough, lower diarrhea, and no active-arm SAEs. 06/18/26:- FDA granted Orphan Drug Designation for IPF. Ph2a GRI-0621-IPF-02 (NCT06331624) met endpoints. 08/24/26:- ERS 2026 presentation of Ph2a GRI-0621-IPF-02 data Sept 5-9, 2026.
Verification
Confirm timing and program details against the company announcement or filing.